Report - für erwachsene CML-Patienten - uniklinikum-jena.deund+... · Imatinib/Dasatinib/Nilotinib mit Asciminib Ziele • MMR, MR4, MR4 .5 unter TKI plus ABL (6, 12, 18, 24 Monate) • Toleranz

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form